Navigation Links
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
Date:7/5/2011

TUESDAY, July 5 (HealthDay News) -- A drug designed to treat certain patients with non-small cell lung cancer boosts survival time without progression of cancer by several months, according to a new study.

The findings reveal that the drug, known as erlotinib (brand name Tarceva), doesn't just boost lifespan, said Dr. Neal E. Ready, associate professor of medical oncology at Duke Cancer Institute, who was not involved with the study. "What you really get is a prolonged period of time when the cancer is under control and someone has a really good quality of life."

This study is the first of its kind to look at Western patients. "Although a growing body of evidence has been emerging about this type of lung cancer, almost all of the studies have been conducted in Asian patients, a group that historically has had significantly different results to [non-small cell lung cancer] therapy compared to Western populations," said principal investigator Dr. Radj Gervais, of the Centre Francois Baclesse in Caen, France, in a news release from the International Association for the Study of Lung Cancer. The association is hosting the World Conference on Lung Cancer in Amsterdam, where the study results were scheduled for presentation Tuesday.

The study of the drug is a phase 3 study. That means it's in the final of three stages of testing that drugs undergo before they can be approved for treatment of a specific disease.

The researchers randomly assigned 174 patients to either erlotinib or platinum-based chemotherapy. Preliminary results showed that about 55 percent of patients responded to the drug, compared to nearly 11 percent to chemotherapy. Patients lived without progression of cancer for 9.4 months with the drug compared to 5.2 months for those who received chemotherapy.

And the median survival was 22.9 months for those who took the drug compared to 18.8 months for those on chemotherapy, the investigators found. '/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2

Related medicine news :

1. Experimental Vaccine Seems to Cure Prostate Cancer in Mice
2. ASCO: Experimental vaccine made from frozen immune cells shows promise for prostate cancer patients
3. Ex-Dallas Maverick survives rare form of leukemia thanks to experimental drug treatment
4. Experimental treatment offers relief from painful prostate condition
5. Christos Mantzoros honored by Federation of the American Societies for Experimental Biology
6. Experimental Test May Warn of Premature Births
7. Experts at Experimental Biology examine dietary cholesterol, egg intake and heart disease risk
8. Experimental Weight-Loss Drug Seems to Work: Study
9. Experimental drug achieves unprecedented weight loss
10. Science at a glance: Symposia, research and special events at Experimental Biology 2011
11. A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Experimental Drug Bests Chemo in Non-Small Cell Lung Cancer Study
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... (PRWEB) , ... August 28, ... ... Services, Inc.’s (AIS) Medicare-Medicaid Dual Eligibles Database have added comprehensive information on ... alignment demonstration approved for a December 2015 launch; and Idaho’s partnership to ...
(Date:8/28/2015)... AB (PRWEB) , ... August 28, 2015 , ... External ... The Heart Fit Clinic is now selling External Counterpulsation (EECP or ECP) machines with ... Heart Fit Clinic has been in business since 2007 helping people prevent and ...
(Date:8/28/2015)... ... 2015 , ... A complimentary webinar offered by healthcare consulting and accounting firm ... proposal to mandate bundled payments through the Comprehensive Care for Joint Replacement Program ... Care for Joint Replacement,” takes place at 12 noon EDT on Wednesday, September 2, ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... Inc. ’s online medical consultations result in high percentages of change to treatment ... the Center for Healthcare Informatics at Tennessee Tech University and analyzed WorldCare’s second ...
Breaking Medicine News(10 mins):Health News:Healthpointe Now Offering Scuba Physicals 2Health News:AIS Duals Database: August Update Finds Two New Duals Programs in Rhode Island and Idaho 2Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:WorldCare International, Inc. Celebrates Findings of Independent ROI Study 2
... Scientists presented new research today demonstrating the impact ... studies examine how such environmental information can be transmitted ... known as epigenetics. This new knowledge could ultimately improve ... and how a parent,s exposure to drugs, alcohol, and ...
... common among cardiac arrest survivors. The survival and ... patients with preexisting cardiomyopathy, compared with those patients ... presented Nov. 14 at the at the American ... Therefore, the researchers recommended the use of therapeutic ...
... research linking alcohol to breast cancer risk, a new study ... that adolescent girls with a family history of breast disease ... cancer have a higher risk of developing benign breast ... without a family history, this already-elevated risk rises with increasing ...
... non-small cell lung cancer who have mutations in the KRAS ... according to results of a recent study conducted by Quintiles ... "Our findings indicate that when patients with lung cancer have ... to antifolate drugs," said lead researcher Sarah Bacus, Ph.D., Quintiles ...
... team of researchers co-led by the University of Pennsylvania ... capable of recording brain activity from the cortical surface ... make possible a whole new generation of brain-computer interfaces ... work was published in Nature Neuroscience. ...
... in people with dangerous heart arrhythmias, according to research ... , Wearable cardioverter defibrillators are used by people who ... including those with weakened heart function, awaiting cardiac transplant ... from receiving an implanted defibrillator. , The device ...
Cached Medicine News:Health News:Nature and nurture work together to shape the brain 2Health News:Hypothermia remains effective in cardiac arrest patients with preexisting cardiomyopathy 2Health News:Girls with family history of breast disease should avoid alcohol 2Health News:Girls with family history of breast disease should avoid alcohol 3Health News:Antifolates show promise against NSCLC subtype 2Health News:A more flexible window into the brain 2Health News:A more flexible window into the brain 3Health News:Wearable defibrillator can prevent death in people with arrhythmias 2
(Date:8/28/2015)... , Aug. 28, 2015 ... the addition of the "Investigation Report on China,s ... Developed by Novartis, ranibizumab was approved by CFDA ... 2012. Currently, only Lucentis, a product of Novartis, is ... as the first self- developed drug for the treatment ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 /PRNewswire/ ... that its shareholders have approved Mylan,s proposed acquisition ... TASE) and the related issuance of Mylan ordinary ... meeting of shareholders held today. The transaction received ... extraordinary general meeting. In addition, the transaction received ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
1000 L, Racked, Pre-sterilized, 100 tips/rack Recommended for 500 and 1000 L pipettes....
Inquire...
300 L, Racked, Filtered, Pre-sterilized, 96 tips/rack Recommended for 250 and 300 L pipettes....
... false signals and contamination caused by ... Barrier Tips offer performance and economy ... (PCR(a)), radioactive isotopes, tissue culture fluids, ... , ,Promega Barrier Tips are made ...
Medicine Products: